UK Charity Starts Early-Stage Clinical Studies Of Lilly's Cdc7 Inhibitor
Executive Summary
The drug development arm of the UK charity, Cancer Research UK, has started early clinical development of potentially a new type of anticancer, a Cdc7 inhibitor, discovered by Eli Lilly, in an effort that could boost traction in this new area of research.